Bristol Myers Squibb @bmsnews · 13 Aug 2026
#MEDIA: @US_FDA granted accelerated approval to our new CELMoD treatment for relapsed or refractory #MultipleMyeloma in adults, introducing a new class of treatment. https://t.co/AjYS3vF6ac https://t.co/Tqf2BELoFy
6 258Views
26Likes
7Reposts
4Replies
2Quotes
2Bookmarks
Is that a lot?
2.86×vs this author's median2 188 views is typical
70Percentile for this authorof 10 recent posts
1.26×vs 100K–1M median4 963 views is typical
4.14%Reachviews ÷ followers
0.62%Engagement rateof viewers reacted